GlassScriptPhysician profile
Branko N Huisa
NPI 1063551000
$13,285.25
in general payments reported to CMS, 2019-2025
55 companies · $3,234 in 2025
The $3,234 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $696 · 2021: $1,933 · 2022: $2,538 · 2023: $2,496 · 2024: $1,892 · 2025: $3,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,538 · Education: $78.49 · Travel and Lodging: $6.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,537.92 |
| Education | $78.49 |
| Travel and Lodging | $6.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,058.41 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,326.27 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Abbott Laboratories | $1,288.01 | 2022-2025 | Infinity, Aveir, Jot Dx |
| Neurocrine Biosciences, INC. | $853.17 | 2021-2025 | Ingrezza |
| Biogen, INC. | $781.47 | 2020-2025 | Vumerity, Tysabri, Tysabri |
| Novartis Pharmaceuticals Corporation | $781.39 | 2020-2025 | |
| Lilly USA, LLC | $637.16 | 2020-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $441.83 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $327.45 | 2021-2025 | Nuplazid |
| Edwards Lifesciences Corporation | $282.65 | 2023 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $275.97 | 2019-2024 | |
| Sk Life Science, INC. | $225.48 | 2020-2022 | |
| Lundbeck LLC | $225.26 | 2020-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $222.87 | 2020-2024 | Valtoco |
| Nevro Corp. | $182.79 | 2022 |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Branko Huisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.